Tiny Gem Archives - Page 9 of 47

FridayJun 14, 2024 9:00 am

InMed Pharmaceuticals Inc. (NASDAQ: INM) Advances Therapies Targeting Neurodegenerative Diseases

INM is advancing INM-089 targeting age-related macular degeneration and INM-901 targeting Alzheimer’s disease The company recently posted positive results for INM-089 demonstrating significant functional and pathological improvements in an AMD disease model Recent preclinical data for INM-901 displayed positive pharmacological effects for treating Alzheimer's disease INM posted a business update for Q3-2024 reporting a closing cash position of US$7.9 million and revenue growth for subsidiary BayMedica, a supplier of rare cannabinoids as ingredients InMed Pharmaceuticals (NASDAQ: INM), a is a clinical stage pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates targeting the CB1/CB2 receptors. InMed’s…

ThursdayJun 13, 2024 9:00 am

Mullen Automotive Inc. (NASDAQ: MULN) Subsidiary Announces First Dealership Deal in Market Projected to See Record Sales

Bloomberg analyst projects 2024 EV sales in the U.S. at nearly 2 million units, making up 13% of new-car purchases Mullen subsidiary inks first commercial dealership agreement with LaFontaine Automotive Group Bollinger Motors expects to start delivering the Bollinger B4 later this year While some headlines in the past few months make it seem like the electric vehicle market is in trouble, a recent “Car and Driver” article forecasts that EV sales are just getting started. Mullen Automotive (NASDAQ: MULN), an emerging EV manufacturer, appears to support that projection, with the recent announcement that its subsidiary, Bollinger Motors, has entered a distribution…

MondayJun 10, 2024 12:00 pm

GEMXX Corp. (GEMZ) Announces Definitive Agreement with Latin Energy Partners in Strategic Latin America Venture

The strategic venture marks a milestone in the company’s expansion into the energy sector, demonstrating GEMXX’s commitment to diversification and growth The project will be overseen by Dinesh Kumar Sarraf, the former chairman and managing director of Oil and Natural Gas Corporation Ltd, India's leading exploration and production company The drilling of the four test wells is set to begin in the coming months, with expected results providing valuable data on the region's oil potential GEMXX (OTC: GEMZ), a publicly traded exploration company engaged in gold, gemstones, oil, and gas, has announced the signing of a Definitive Agreement with Latin…

MondayJun 10, 2024 9:45 am

Mullen Automotive Inc. (NASDAQ: MULN) Class 3 EV Truck Receives CARB Certification, Joins Class 1 EV Van in Meeting Stringent Emission Standards

CARB certification is awarded to vehicle manufacturers that meet specific emissions standards in compliance with CARB regulations CARB is charged with protecting public from harmful effects of air pollution, developing programs and actions to fight climate change “Having both our Class 1 and Class 3 commercial EVs now CARB and EPA certified will continue to drive sales in all states across America,” says Mullen CEO With environmental concerns becoming an increasing priority, more states, companies, and consumers are paying attention to — and prioritizing — environmentally friendly products and practices. Mullen Automotive (NASDAQ: MULN), an emerging EV manufacturer, shares this commitment to being…

ThursdayJun 06, 2024 9:00 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Grows Patent Portfolio to 43 Granted Patents Worldwide

Lexaria recently received two new patents granted in the U.S. in its patent families #21 and #24 The new patents complement the company’s efforts in investigating the capabilities of DehydraTECH-CBD to lower blood pressure in humans with hypertension and mitigate epileptic seizures in rodents The company relies on R&D to provide data that enables it to apply for patent protection, supports further investigations and discoveries, as well as increases its chances of potentially receiving FDA approvals According to CEO Chris Bunka, the company’s growing patent portfolio forms the foundation upon which the company forges commercial relationships Lexaria Bioscience (NASDAQ: LEXX),…

FridayMay 31, 2024 9:45 am

GEMXX Corp. (GEMZ) Enters Alliance with Latin Energy Partners to Advance Groundbreaking Developments in Oil Exploration in Latin America

GEMXX recently entered a significant partnership with Latin Energy Partners that has seen the two companies define terms to jointly drill four test wells in a promising geologic formation in a Latin American country The partnership is part of GEMXX’s plans to strategically expand its current successful business model, diversifying its business portfolio, and exploring new underground resource opportunities Latin America has large tracts and regions of under-explored sedimentary basins which hold significant oil and gas resources potential Preliminary explorations in the two basins suggest potential for more than 1 billion barrels each of recoverable oil, positioning GEMXX and Latin…

TuesdayMay 28, 2024 10:30 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Concludes First Dosing for its Second GLP-1 Human Pilot Study; Maintains Study Pace and Rollout for 2024

Lexaria, a global innovator in drug delivery platforms, just concluded its first dosing for its glucagon-peptide-1 (“GLP-1”) human pilot study #2, GLP-1-H24-2 GLP-1, a class of drugs, has demonstrated the ability to address diabetes and weight loss, albeit with poor oral bioavailability, usually as little as 0.8% Lexaria, through its study, looks to demonstrate the effectiveness of its DehydraTECH(TM) technology in improving GLP-1’s bioavailability, opening up a vast worldwide market Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, just concluded its first dosing for its glucagon-peptide-1 (“GLP-1”) human pilot study #2, GLP-1-H24-2 (https://ibn.fm/74Pee). This follows the recent…

TuesdayMay 21, 2024 10:30 am

GEMXX Corp. (GEMZ) Expands to Oil and Gas Exploration Ventures, Creating New Strategic Partnerships in Industry

In an expansion of operations, GEMXX plans to finance the exploration of extensive oil reserves, specifically targeting giant fields with reserves of 500 million barrels and super-giant fields with over 3 billion barrels located primarily in Latin America By leveraging a comprehensive network in the oil and gas sector, GEMXX plans to develop strong strategic partnerships and secure funding to propel exploration efforts quickly GEMXX has also announced Richard Clowater as the new Chief Executive Officer and Chairman of the Board, and the appointment of Deane Preston to its Board of Directors, effective May 15, 2024 GEMXX (OTC: GEMZ), an…

TuesdayMay 14, 2024 9:45 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Partners with the National Research Council of Canada for DehydraTECH-GLP-1 Mode of Action Investigation

Lexaria, a global innovator in drug delivery platforms, just announced its newest relationship with the National Research Council of Canada (“NRC”) Specific molecular characteristics of the glucagon-peptide 1 (“GLP-1”) drug, semaglutide, processed with Lexaria’s patented DehydraTECH(TM) technology, will be evaluated Previous research has shown that using a DehydraTECH-semaglutide capsule composition yields a 43% higher peak level of semaglutide in blood compared to Rybelsus(R). This has potential for increased weight-loss and diabetic control Lexaria’s management is confident that this partnership will complement the company’s animal and human pharmacokinetic and pharmacodynamic studies for the 2024 calendar year Lexaria Bioscience (NASDAQ: LEXX), a…

ThursdayMay 09, 2024 9:45 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Set to Extend Operational Runway to 2025 Following Warrant Exercise and Issuance

Lexaria has entered an agreement wherein an existing accredited investor has exercised all their warrants to purchase shares The company has received $4.7 million from this undertaking, prior to deducting estimated offering expenses Proceeds fully fund Lexaria’s entire planned 2024 GLP-1 R&D program, leaving additional excess capital for general purposes Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, just announced its entry into a warrant exercise agreement with an existing accredited investor to exercise in full certain existing warrants initially issued in October 2023 and February 2024. The warrants will be exercised at $0.97 and $2.185 per…

Spotlighting undiscovered companies with enormous upside potential.

Contact us: (512) 354-7000

Category: Tiny Gem